280 related articles for article (PubMed ID: 19674937)
1. Novel cytokine-targeted therapies and intestinal inflammation.
Waldner MJ; Neurath MF
Curr Opin Pharmacol; 2009 Dec; 9(6):702-7. PubMed ID: 19674937
[TBL] [Abstract][Full Text] [Related]
2. Homeostatic (IL-7) and effector (IL-17) cytokines as distinct but complementary target for an optimal therapeutic strategy in inflammatory bowel disease.
Kanai T; Nemoto Y; Kamada N; Totsuka T; Hisamatsu T; Watanabe M; Hibi T
Curr Opin Gastroenterol; 2009 Jul; 25(4):306-13. PubMed ID: 19448533
[TBL] [Abstract][Full Text] [Related]
3. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease.
Nakase H; Okazaki K; Tabata Y; Chiba T
J Gastroenterol; 2003 Mar; 38 Suppl 15():59-62. PubMed ID: 12698874
[TBL] [Abstract][Full Text] [Related]
4. Cytokine blockade in inflammatory bowel diseases.
Perrier C; Rutgeerts P
Immunotherapy; 2011 Nov; 3(11):1341-52. PubMed ID: 22053885
[TBL] [Abstract][Full Text] [Related]
5. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies.
Van Assche G; Vermeire S; Rutgeerts P
Gastroenterol Clin North Am; 2006 Dec; 35(4):743-56. PubMed ID: 17129811
[TBL] [Abstract][Full Text] [Related]
6. TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases.
Schenk M; Bouchon A; Seibold F; Mueller C
J Clin Invest; 2007 Oct; 117(10):3097-106. PubMed ID: 17853946
[TBL] [Abstract][Full Text] [Related]
7. Novel drug delivery strategies for the treatment of inflammatory bowel disease.
Kesisoglou F; Zimmermann EM
Expert Opin Drug Deliv; 2005 May; 2(3):451-63. PubMed ID: 16296767
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in biological therapy for inflammatory bowel disease.
Kurtovic J; Segal I
Trop Gastroenterol; 2004; 25(1):9-14. PubMed ID: 15303463
[TBL] [Abstract][Full Text] [Related]
9. Cytokines and inflammatory bowel disease.
Anand AC; Adya CM
Trop Gastroenterol; 1999; 20(3):97-106. PubMed ID: 10695414
[TBL] [Abstract][Full Text] [Related]
10. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease.
Hibi T; Inoue N; Ogata H; Naganuma M
J Gastroenterol; 2003 Mar; 38 Suppl 15():36-42. PubMed ID: 12698869
[TBL] [Abstract][Full Text] [Related]
11. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe?
Reuter BK; Pizarro TT
Eur J Immunol; 2004 Sep; 34(9):2347-55. PubMed ID: 15307167
[TBL] [Abstract][Full Text] [Related]
12. New cytokine therapeutics for inflammatory bowel disease.
Stokkers PC; Hommes DW
Cytokine; 2004 Nov 21-Dec 7; 28(4-5):167-73. PubMed ID: 15588691
[TBL] [Abstract][Full Text] [Related]
13. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease.
Melgar S; Karlsson L; Rehnström E; Karlsson A; Utkovic H; Jansson L; Michaëlsson E
Int Immunopharmacol; 2008 Jun; 8(6):836-44. PubMed ID: 18442787
[TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
15. Cytokines in inflammatory bowel disease.
Kmieć Z
Arch Immunol Ther Exp (Warsz); 1998; 46(3):143-55. PubMed ID: 9704146
[TBL] [Abstract][Full Text] [Related]
16. Immune dysfunction in inflammatory bowel disease.
Neuman MG
Transl Res; 2007 Apr; 149(4):173-86. PubMed ID: 17383591
[TBL] [Abstract][Full Text] [Related]
17. Experimental models of inflammatory bowel disease.
Stadnicki A; Colman RW
Arch Immunol Ther Exp (Warsz); 2003; 51(3):149-55. PubMed ID: 12894869
[TBL] [Abstract][Full Text] [Related]
18. Gene transfer approaches for the treatment of inflammatory bowel disease.
Wirtz S; Neurath MF
Gene Ther; 2003 May; 10(10):854-60. PubMed ID: 12732871
[TBL] [Abstract][Full Text] [Related]
19. Mucosal T cells as a target for treatment of IBD.
Watanabe M; Yamazaki M; Kanai T
J Gastroenterol; 2003 Mar; 38 Suppl 15():48-50. PubMed ID: 12698871
[TBL] [Abstract][Full Text] [Related]
20. Animal models of intestinal inflammation: clues to the pathogenesis of inflammatory bowel disease.
Powrie F; Uhlig H
Novartis Found Symp; 2004; 263():164-74; discussion 174-8, 211-8. PubMed ID: 15669641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
